Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis.
Although depressive symptoms in first episode psychosis have been associated with cannabis abuse, their influence on the long-term functional course of FEP patients who abuse cannabis is unknown. The aims of the study were to examine the influence of subclinical depressive symptoms on the long-term...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4398379?pdf=render |
| _version_ | 1828544610546221056 |
|---|---|
| author | Itxaso González-Ortega Susana Alberich Enrique Echeburúa Felipe Aizpuru Eduardo Millán Eduard Vieta Carlos Matute Ana González-Pinto |
| author_facet | Itxaso González-Ortega Susana Alberich Enrique Echeburúa Felipe Aizpuru Eduardo Millán Eduard Vieta Carlos Matute Ana González-Pinto |
| author_sort | Itxaso González-Ortega |
| collection | DOAJ |
| description | Although depressive symptoms in first episode psychosis have been associated with cannabis abuse, their influence on the long-term functional course of FEP patients who abuse cannabis is unknown. The aims of the study were to examine the influence of subclinical depressive symptoms on the long-term outcome in first episode-psychosis patients who were cannabis users and to assess the influence of these subclinical depressive symptoms on the ability to quit cannabis use.64 FEP patients who were cannabis users at baseline were followed-up for 5 years. Two groups were defined: (a) patients with subclinical depressive symptoms at least once during follow-up (DPG), and (b) patients without subclinical depressive symptoms during follow-up (NDPG). Psychotic symptoms were measured using the Positive and Negative Syndrome Scale (PANSS), depressive symptoms using the Hamilton Depression Rating Scale (HDRS)-17, and psychosocial functioning was assessed using the Global Assessment of Functioning (GAF). A linear mixed-effects model was used to analyze the combined influence of cannabis use and subclinical depressive symptomatology on the clinical outcome.Subclinical depressive symptoms were associated with continued abuse of cannabis during follow-up (β= 4.45; 95% confidence interval [CI]: 1.78 to 11.17; P = .001) and with worse functioning (β = -5.50; 95% CI: -9.02 to -0.33; P = .009).Subclinical depressive symptoms and continued cannabis abuse during follow-up could be predictors of negative outcomes in FEP patients. |
| first_indexed | 2024-12-12T02:32:34Z |
| format | Article |
| id | doaj.art-06c37a7f0f9b4451aee143d89af77089 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-12T02:32:34Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-06c37a7f0f9b4451aee143d89af770892022-12-22T00:41:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012370710.1371/journal.pone.0123707Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis.Itxaso González-OrtegaSusana AlberichEnrique EcheburúaFelipe AizpuruEduardo MillánEduard VietaCarlos MatuteAna González-PintoAlthough depressive symptoms in first episode psychosis have been associated with cannabis abuse, their influence on the long-term functional course of FEP patients who abuse cannabis is unknown. The aims of the study were to examine the influence of subclinical depressive symptoms on the long-term outcome in first episode-psychosis patients who were cannabis users and to assess the influence of these subclinical depressive symptoms on the ability to quit cannabis use.64 FEP patients who were cannabis users at baseline were followed-up for 5 years. Two groups were defined: (a) patients with subclinical depressive symptoms at least once during follow-up (DPG), and (b) patients without subclinical depressive symptoms during follow-up (NDPG). Psychotic symptoms were measured using the Positive and Negative Syndrome Scale (PANSS), depressive symptoms using the Hamilton Depression Rating Scale (HDRS)-17, and psychosocial functioning was assessed using the Global Assessment of Functioning (GAF). A linear mixed-effects model was used to analyze the combined influence of cannabis use and subclinical depressive symptomatology on the clinical outcome.Subclinical depressive symptoms were associated with continued abuse of cannabis during follow-up (β= 4.45; 95% confidence interval [CI]: 1.78 to 11.17; P = .001) and with worse functioning (β = -5.50; 95% CI: -9.02 to -0.33; P = .009).Subclinical depressive symptoms and continued cannabis abuse during follow-up could be predictors of negative outcomes in FEP patients.http://europepmc.org/articles/PMC4398379?pdf=render |
| spellingShingle | Itxaso González-Ortega Susana Alberich Enrique Echeburúa Felipe Aizpuru Eduardo Millán Eduard Vieta Carlos Matute Ana González-Pinto Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. PLoS ONE |
| title | Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. |
| title_full | Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. |
| title_fullStr | Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. |
| title_full_unstemmed | Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. |
| title_short | Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis. |
| title_sort | subclinical depressive symptoms and continued cannabis use predictors of negative outcomes in first episode psychosis |
| url | http://europepmc.org/articles/PMC4398379?pdf=render |
| work_keys_str_mv | AT itxasogonzalezortega subclinicaldepressivesymptomsandcontinuedcannabisusepredictorsofnegativeoutcomesinfirstepisodepsychosis AT susanaalberich subclinicaldepressivesymptomsandcontinuedcannabisusepredictorsofnegativeoutcomesinfirstepisodepsychosis AT enriqueecheburua subclinicaldepressivesymptomsandcontinuedcannabisusepredictorsofnegativeoutcomesinfirstepisodepsychosis AT felipeaizpuru subclinicaldepressivesymptomsandcontinuedcannabisusepredictorsofnegativeoutcomesinfirstepisodepsychosis AT eduardomillan subclinicaldepressivesymptomsandcontinuedcannabisusepredictorsofnegativeoutcomesinfirstepisodepsychosis AT eduardvieta subclinicaldepressivesymptomsandcontinuedcannabisusepredictorsofnegativeoutcomesinfirstepisodepsychosis AT carlosmatute subclinicaldepressivesymptomsandcontinuedcannabisusepredictorsofnegativeoutcomesinfirstepisodepsychosis AT anagonzalezpinto subclinicaldepressivesymptomsandcontinuedcannabisusepredictorsofnegativeoutcomesinfirstepisodepsychosis |